PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF HEPATIC FIBROSIS AND LIVER CIRRHOSIS COMPRISING RAMALIN
PURPOSE: A pharmaceutical composition for preventing or treating hepatic fibrosis or liver cirrhosis is provided to effectively suppress hepatic fibrosis without cytotoxicity to normal hepatocytes using ramalin, thereby effectively preventing or treating hepatic fibrosis and liver cirrhosis. CONSTITUTION: A pharmaceutical composition for preventing or treating hepatic fibrosis or liver cirrhosis contains a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient. A functional food for preventing or treating hepatic fibrosis or liver cirrhosis contains the compound or a sitologically acceptable salt thereof as an active ingredient. A pharmaceutical composition for preventing or treating hepatic fibrosis or liver cirrhosis contains a Ramalina terebrata extract containing the compound of chemical formula 1 as an active ingredient..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Europäisches Patentamt - (2018) vom: 27. Sept. Zur Gesamtaufnahme - year:2018 |
|---|
| Sprache: |
Unbestimmt |
|---|
| Beteiligte Personen: |
YIM JOUNG HAN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), Last update posted on www.epo.org: 2018-09-27, Last updated: 2021-03-11 |
|---|
| Patentnummer: |
KR20130098745 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA006644120 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA006644120 | ||
| 003 | DE-627 | ||
| 005 | 20230504145959.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210531s2018 xx |||||o 00| ||und c | ||
| 035 | |a (DE-627)EPA006644120 | ||
| 035 | |a (EPA)KR20130098745 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a und | ||
| 100 | 0 | |a YIM JOUNG HAN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF HEPATIC FIBROSIS AND LIVER CIRRHOSIS COMPRISING RAMALIN |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), Last update posted on www.epo.org: 2018-09-27, Last updated: 2021-03-11 | ||
| 520 | |a PURPOSE: A pharmaceutical composition for preventing or treating hepatic fibrosis or liver cirrhosis is provided to effectively suppress hepatic fibrosis without cytotoxicity to normal hepatocytes using ramalin, thereby effectively preventing or treating hepatic fibrosis and liver cirrhosis. CONSTITUTION: A pharmaceutical composition for preventing or treating hepatic fibrosis or liver cirrhosis contains a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient. A functional food for preventing or treating hepatic fibrosis or liver cirrhosis contains the compound or a sitologically acceptable salt thereof as an active ingredient. A pharmaceutical composition for preventing or treating hepatic fibrosis or liver cirrhosis contains a Ramalina terebrata extract containing the compound of chemical formula 1 as an active ingredient. | ||
| 650 | 4 | |a A61K | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61P | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a KIM IL CHAN |e verfasserin |4 aut | |
| 700 | 0 | |a KIM DOC KYU |e verfasserin |4 aut | |
| 700 | 0 | |a HAN SE JONG |e verfasserin |4 aut | |
| 700 | 0 | |a LEE HYOUNG SEOK |e verfasserin |4 aut | |
| 700 | 0 | |a HARI DATTA BHATTARAI |e verfasserin |4 aut | |
| 700 | 0 | |a YANG SU GEUN |e verfasserin |4 aut | |
| 700 | 0 | |a LEE DON HANG |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2018) vom: 27. Sept. |
| 773 | 1 | 8 | |g year:2018 |g day:27 |g month:09 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/searchResults?DB=EPODOC&locale=en_EP&query=KR20130098745A |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | u | w | |j 2018 |b 27 |c 09 |
| 951 | |a AR | ||
| 952 | |j 2018 |b 27 |c 09 | ||